Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Novo Nordisk loses further ground in obesity market

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Asian shares sink after losses for Big Tech pull US stocks lower

Tokyo's benchmark Nikkei 225 index has dipped more than 4% and most other markets in Asia also sank after a retreat on Wall ...

Novo Nordisk cuts 2025 forecast again, cites slower sales of Wegovy and Ozempic

Novo Nordisk A/S (NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of its ...

Novo Nordisk A/S: Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted by one-off restructuring costs of around DKK 9 billion related to the ...